logo
Johnson City Schools reach $60k goal for new STARLAB

Johnson City Schools reach $60k goal for new STARLAB

Yahoo23-04-2025

JOHNSON CITY, Tenn. (WJHL) — The Johnson City Public Schools Foundation (JCPSF) announced Wednesday it reached a $60,000 goal for a new STARLAB.
Funds raised through the 2025 SPELL-A-BRATION will allow the purchase of the traveling, digital and mobile planetarium STARLAB unit.
JCPSF President Tembra Aldridge said the lab should be available by fall for Johnson City Schools.
Kids with TennCare face major hurdles finding dentists
'This is due to the efforts of many in our region, but we could not have done it without the community coming together for the students in our Johnson City schools,' Aldridge said in a news release. 'SPELL-A-BRATION 2025 itself brought twenty-three teams from various schools and businesses together for that fun evening at Science Hill High School. In addition, we had a great deal of local support from sponsors.'
The mobile planetarium will travel throughout Johnson City elementary and public schools.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

World Precision Instruments and SynVivo Launch Next-Generation Multiplexed TEER-on-a-Chip Platform for Real-Time Organ-on-a-Chip Cell Monitoring
World Precision Instruments and SynVivo Launch Next-Generation Multiplexed TEER-on-a-Chip Platform for Real-Time Organ-on-a-Chip Cell Monitoring

Yahoo

time5 hours ago

  • Yahoo

World Precision Instruments and SynVivo Launch Next-Generation Multiplexed TEER-on-a-Chip Platform for Real-Time Organ-on-a-Chip Cell Monitoring

SARASOTA, Fla. and HUNTSVILLE, Ala., June 11, 2025 /PRNewswire/ -- World Precision Instruments (WPI), a global leader in transepithelial electrical resistance (TEER) instrumentation, and SynVivo Inc., a pioneer in Organ-on-a-Chip (OOC) technology, today announced the commercial launch of a next-generation multiplexed TEER-on-a-Chip platform—a breakthrough solution enabling real-time, high-throughput measurement of barrier integrity in advanced Organ-on-a-Chip models. The co-developed platform integrates WPI's gold-standard EVOM™ measurement technology with SynVivo's SynTEER™ multiplexed OOC models with embedded electrodes, providing researchers with a seamless solution for performing TEER measurements directly within microfluidic chips. Initially validated on SynVivo's advanced SynBBB™ Blood-Brain Barrier model, this is the first in a planned series of Organ-on-a-Chip platforms powered by the new EVOM-Chip™ system from WPI. With electrodes embedded directly into SynVivo's SynTEER™ multiplexed OOC models researchers can now perform real-time TEER measurements across multiple channels—enabling continuous barrier monitoring, streamlined workflows, and improved reproducibility. The EVOM-Chip™ system allows for hands-free, simultaneous data collection, and remains fully compatible with live-cell imaging and physiologically relevant flow conditions. "This collaboration represents a major advancement in functional barrier modeling," said Gwen Fewell, President & CEO of SynVivo Inc. "Integrating TEER measurement directly into our chip enhances data fidelity, reduces variability, and streamlines experimental workflows—key to enabling more predictive, standardized and scalable in vitro models. By combining our vascularized OOC technology with WPI's industry-leading TEER measurement expertise, we're delivering a powerful solution for researchers tackling complex questions in CNS drug development, inflammation, and drug discovery." WPI's EVOM™ family of TEER instrumentation has set the standard for barrier function assessment for over 30 years. SynVivo's SynTEER™ platform builds on this legacy with pre-integrated, precisely aligned electrodes designed to optimize TEER signal fidelity across a range of Organ-on-a-Chip applications. As the OOC market rapidly grows, it continues to face challenges around standardization and automation, both of which are essential for mainstream adoption in pharmaceutical research. "A critical gap has been the ability to perform on-chip, non-destructive sensing—particularly TEER measurements—a need shared by the majority of OOC platforms but rarely implemented successfully or in a multiplex fashion," explains Mark Rutledge, CEO of WPI. "With EVOM™ Chip, researchers can monitor their OOC platforms from cell seeding through barrier formation, as well as before, during and after drug treatment, to get accurate and reproducible readouts, without affecting the health or well-being of the cells." The system's initial application on the SynBBB™ Blood-Brain Barrier platform has demonstrated a strong correlation between electrical resistance and functional barrier properties, supporting its use in CNS drug development, inflammation studies, and neurovascular research. See It Live at MPS World Summit – Brussels, June 10–13, 2025Visit WPI and SynVivo at the MPS World Summit to explore the EVOM-Chip™ and SynTEER-on-a-Chip systems in action and learn how integrated TEER-on-Chip technology can accelerate your research. WPI Booth #131 SynVivo Booth #404 ABOUT WORLD PRECISION INSTRUMENTS For over 55 years, World Precision Instruments (WPI) has been a leading global manufacturer and provider of innovative research equipment and laboratory supplies to the life sciences, pharmaceutical, health care, and industrial markets. Our proven technology supports complex model development, including preclinical models and organ-on-a-chip systems, providing researchers with the tools to identify and validate drugs to understand mechanism of action, dosage, administration, drug-drug interactions, patient-specific reactions, pharmacokinetics, pharmacodynamics, safety and efficacy. Our areas of innovation focus on tissue and cell biology, fluidics, animal physiology and electrophysiology. With an extensive global network and a passion for innovation, WPI provides novel solutions to customers' daily challenges. For more information, visit About SynVivoSynVivo is a pioneering organ-on-chip company developing physiologically relevant tissue models for drug discovery, disease research, and safety testing. Its advanced microfluidic platforms replicate human tissue microenvironments to enhance the predictive accuracy of in vitro testing. SynVivo is committed to bridging the gap between traditional preclinical models and human clinical outcomes, advancing a new standard in predictive, human-relevant drug development. View original content to download multimedia: SOURCE SynVivo and World Precision Instruments Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Physicists Actually Made The 'World's Smallest Violin' For a Serious Reason
Physicists Actually Made The 'World's Smallest Violin' For a Serious Reason

Yahoo

time18 hours ago

  • Yahoo

Physicists Actually Made The 'World's Smallest Violin' For a Serious Reason

You may hear references to playing the world's smallest violin when someone is being overly whiny or wallowing in self-pity, and now scientists have turned the joke into an actual microscopic object. Physicists at Loughborough University in the UK deployed the latest in nanolithography techniques – etching patterns into materials at the smallest possible scales – to create a violin drawing that's just 13 microns wide. That's thinner than a human hair, which are typically up to 180 microns in diameter. This is essentially just a drawing rather than an instrument, and you would have to be a tiny tardigrade to play it anyway, but the novel creation demonstrates ways in which the next generation of electronic devices could be made. "Once we understand how materials behave, we can start applying that knowledge to develop new technologies, whether it's improving computing efficiency or finding new ways to harvest energy," says experimental physicist Kelly Morrison, from Loughborough University. "But first, we need to understand the fundamental science, and this system enables us to do just that." The violin was made through a four-step process. First, an incredibly fine, heated needle was used to draw the violin pattern into a chip coated with a polymer. Second, the part of the polymer that's been written on is dissolved. The third stage is filling the newly formed cavity in the polymer with platinum, which is the material the violin is actually made from. The fourth and final step is removing the chip and the rest of the polymer, leaving behind the violin. It's not unlike the process of screen printing, where ink is pressed through a stencil to create a picture on the underlying layer – though in this case the scale is much, much smaller, and the equipment is much, much more sophisticated. This is a seriously delicate process, and requires equipment that takes up a whole room. The setup includes a sculpting machine called a NanoFrazor, which is enclosed in a glove box to keep out dust and other particles. "I'm really excited about the level of control and possibilities we have with the setup," says Morrison. "I'm looking forward to seeing what I can achieve – but also what everyone else can do with the system." More ambitious research is now planned for the NanoFrazor and its connected software, work that will involve different materials and different methods of customizing them at the smallest possible scales. And any time that improvements in miniaturization are made, they have implications for technologies including computing. For now, this is certainly the smallest violin that we've ever come across – continuing the tradition of the phrase thought to have first been popularized by a mention in the TV series M*A*S*H back in the 1970s. "Though creating the world's smallest violin may seem like fun and games, a lot of what we've learned in the process has actually laid the groundwork for the research we're now undertaking," says Morrison. "Our nanolithography system allows us to design experiments that probe materials in different ways – using light, magnetism, or electricity – and observe their responses." Spiral Magnetism Seen in Synthetic Crystal For The First Time We've Been Misreading a Major Law of Physics For Nearly 300 Years Big Bang May Not Be The Beginning of Everything, New Theory Suggests

ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore
ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore

Yahoo

time2 days ago

  • Yahoo

ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore

SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedTech ventures in Singapore. This partnership will support venture creation, product development, and commercialisation by bringing together ClavystBio and two national initiatives hosted by A*STAR — MedTech Catapult and the Diagnostics Development Hub (DxD Hub) — along with A*STAR's broader MedTech and venture creation capabilities. The partnership comes amid growing momentum in Singapore's biomedical landscape, with MedTech output reaching S$20 billion in 2023.[1] As Asia's MedTech market is projected to grow to US$225 billion (S$304 billion) by 2030,[2] these efforts aim to better position Singapore-based innovations to scale and enter new markets. Over this two-year partnership, the parties will work towards the co-creation of new MedTech ventures, investments into A*STAR affiliated companies, and fostering collaborations between A*STAR and ClavystBio's portfolio companies. By combining complementary strengths — from research and engineering to venture building and funding — the partnership aims to identify promising technologies, shape MedTech projects for market readiness, and support new venture formation to strengthen Singapore's innovation-driven MedTech ecosystem. The partnership will focus on several key areas: Fostering new ventures from research: A*STAR and ClavystBio will jointly identify promising research and technologies to venture build new MedTech companies. A*STAR will contribute deep scientific expertise and structured venture creation support, while ClavystBio will provide access to venture and growth capital, expert guidance, and its extensive network to launch and scale these early-stage companies. Advancing MedTech product development: MedTech Catapult will support the development of medical devices through engineering design, prototyping, and manufacturing translation, while ClavystBio will draw on its investment and industry relationships to explore potential commercial pathways for promising innovations. Accelerating commercial readiness in diagnostics and digital health: DxD Hub and ClavystBio will shape ventures in this space with strong commercial potential. DxD Hub will bring technical and productisation expertise — including in AI-powered software, multi-omics, and point-of-care diagnostics — to refine innovations for commercial viability. ClavystBio will contribute its venture investing and venture building expertise to drive commercialisation. Strengthening Singapore's MedTech ecosystem: To support long-term sector growth, the partners will assess Singapore's MedTech manufacturing, design, and regulatory support landscape. MedTech Catapult will lead efforts to map ecosystem capabilities and identify gaps, while ClavystBio will explore investment opportunities in companies with specialised technologies that can strengthen Singapore's MedTech value chain. "This partnership highlights ClavystBio's commitment to nurturing globally successful medical devices, digital health, and diagnostics companies from Singapore," said Mr Anselm Tan, Digital Health & MedTech Lead at ClavystBio. "By combining ClavystBio's investment and venture-building expertise with A*STAR's deep scientific capabilities and productisation platforms, we are cultivating an ecosystem primed for innovation and commercial success. "A*STAR is committed to nurturing a dynamic MedTech ecosystem that bridges innovation with deep tech companies," said Ms Irene Cheong, Assistant Chief Executive (Innovation & Enterprise) at A*STAR. "This MoU builds on an existing collaboration with ClavystBio and marks a significant step forward in our joint efforts to co-create and grow globally investible MedTech ventures. Through national productisation platforms like MedTech Catapult and DxD Hub, combined with A*STAR's venture creation capabilities, we aim to commercialise more innovations from lab to market and grow a vibrant MedTech ecosystem in Singapore." [1] Speech by SMS Low Yen Ling at the MedTech Forum[2] Singapore's MedTech sector and locally made medical devices punching above their weight | Singapore EDB About ClavystBio ClavystBio is a life sciences investor and venture builder set up by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing start-ups together, we foster a vibrant and supportive community. About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit About Diagnostics Development Hub (DxD Hub) The Diagnostics Development Hub is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub aims to accelerate the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption. Through impactful products, empowering local enterprises and anchoring global companies in Singapore, DxD Hub contributes to the development of an effective diagnostic devices' ecosystem in Singapore. For ongoing news, visit About MedTech Catapult MedTech Catapult (MC) is a national initiative designed to accelerate the product development and commercialisation of high-value life science instruments and regulated medical devices. MC partners with product owners, local contract manufacturers (CMs), and leverages external design houses, and other key stakeholders to guide innovations from concept to market. Their goal is to strengthen Singapore's medtech ecosystem by providing dedicated engineering, quality assurance, regulatory affairs, clinical affairs, project management and commercialisation support to derisk and support products towards commercialisation and market adoption whilst supporting pull-through to local manufacturing. View original content to download multimedia: SOURCE ClavystBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store